Se connecter Inscription gratuite

Kazia Therapeutics Revenu

Quel est le Revenu de Kazia Therapeutics?

Le Revenu de Kazia Therapeutics Limited est -AUD$24.65

Quelle est la définition de Revenu?

Le résultat net disponible pour les actionnaires ordinaires correspond au résultat net moins les dividendes privilégiés versés.

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

Revenu des entreprises dans Health Care secteur sur ASX par rapport à Kazia Therapeutics

Que fait Kazia Therapeutics?

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Entreprises avec revenu similaire à Kazia Therapeutics